C2 Therapeutics Announces Initiation of Coldplay III Trial Validating the C2 CryoBalloon™ Focal Ablation System

Posted by Ellie Martinez on Jun 07, 2016

REDWOOD CITY, Calif.--C2 Therapeutics today announced the initiation of its Coldplay III trial with treatment of the first patient at University Hospitals in northeast Ohio. The patient was treated with the C2 CryoBalloon™ Focal Ablation System by John Dumot, D.O., Director, Digestive Health Institute, University Hospitals, commencing the clinical trial to validate the efficacy and safety of the system.


US ONLY: The Coldplay CryoBalloon™ Ablation System is intended for use as a cryosurgical tool in the field of general surgery, specifically for endoscopic applications, to include ablation of Barrett’s Esophagus with high grade dysplasia.


EU ONLY: The CryoBalloon Focal Ablation System is used to ablate unwanted tissue in the gastrointestinal tract, including treatment of Barrett’s Esophagus and squamous dysplasia, by application of extreme cold.

C2 Therapeutics

303 Convention Way
Suite 1
Redwood City, CA 94063
(866) 515-3861